Rhumbline Advisers Takes Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Rhumbline Advisers acquired a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 65,287 shares of the company’s stock, valued at approximately $216,000. Rhumbline Advisers owned approximately 0.11% of Pyxis Oncology as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Vestal Point Capital LP bought a new stake in Pyxis Oncology during the fourth quarter valued at $792,000. Bank of New York Mellon Corp boosted its position in shares of Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock valued at $1,031,000 after acquiring an additional 149,522 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Pyxis Oncology during the first quarter worth about $351,000. Cable Car Capital LLC bought a new position in shares of Pyxis Oncology in the fourth quarter worth approximately $111,000. Finally, SG Americas Securities LLC purchased a new stake in Pyxis Oncology in the first quarter valued at approximately $59,000. Institutional investors own 39.09% of the company’s stock.

Wall Street Analysts Forecast Growth

PYXS has been the topic of several research reports. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. Stifel Nicolaus initiated coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $9.00.

Pyxis Oncology Stock Down 2.7 %

Pyxis Oncology stock opened at $3.62 on Friday. The firm has a fifty day simple moving average of $3.61 and a two-hundred day simple moving average of $3.91. Pyxis Oncology, Inc. has a twelve month low of $1.35 and a twelve month high of $6.85. The company has a market capitalization of $215.10 million, a PE ratio of -2.66 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, equities analysts expect that Pyxis Oncology, Inc. will post -1.07 earnings per share for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.